Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE S F versus METAPROTERENOL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE S F versus METAPROTERENOL SULFATE.
ISOETHARINE HYDROCHLORIDE S/F vs METAPROTERENOL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Selective beta-2 adrenergic receptor agonist that activates adenylate cyclase, increasing intracellular cyclic AMP leading to bronchodilation and inhibition of mast cell mediator release.
Inhalation: 1-2 inhalations of a 340 mcg/metered dose every 4 hours as needed. Nebulization: 500 mcg (0.5 mL of a 0.1% solution) every 4 hours as needed.
2.5 mg (0.25 mL of 1% solution) by nebulization every 6-8 hours. For oral, 20 mg every 6-8 hours.
None Documented
None Documented
2-4 hours; clinical context: short half-life supports continuous or repeated dosing for acute bronchospasm.
Terminal elimination half-life: 2-6 hours. Clinical context: Shorter half-life requires frequent dosing; prolongation in renal impairment.
Primarily renal excretion of unchanged drug and metabolites; 60-70% excreted in urine as unchanged drug and sulfate conjugates, with less than 10% eliminated in feces via biliary excretion.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist